Advancing Rare Disease Care: Insights from the World Orphan Drug Congress and AAN Annual Meeting
The World Orphan Drug Congress (WODC) and the American Academy of Neurology (AAN) Annual Meeting are where healthcare leaders, advocates,…
![Advancing Rare Disease Care: Insights from the World Orphan Drug Congress and AAN Annual Meeting](https://anovorx.com/wp-content/uploads/2024/06/ANOVO-0086-Q2-WODC-ANN-Logos-v1.1.jpg)
![Pyros and Anovo Partner to Elevate Care for Infantile Spasms](https://anovorx.com/wp-content/uploads/2024/04/Partnership-Post-Pyros-Pharmaceuticals.jpeg)
Pyros and Anovo Partner to Elevate Care for Infantile Spasms
Pyros Pharmaceuticals works to elevate the standard of care for children with rare disease by pioneering treatment options like VIGPODER™…
April 1, 2024
![Jill’s Story: Advocating for Patients with Acromegaly](https://anovorx.com/wp-content/uploads/2024/04/Patient-Video-Jills-Story-Advocating-for-Patients-with-Acromegaly.jpeg)
Jill’s Story: Advocating for Patients with Acromegaly
Jill Sisco isn’t just an advocate – she’s also a patient herself. She’s been living with Acromegaly, a rare disease…
March 6, 2024
![Celebrating Five Consecutive Years as a Top Workplace at Anovo](https://anovorx.com/wp-content/uploads/2024/04/top-workplaces.jpeg)
Celebrating Five Consecutive Years as a Top Workplace at Anovo
We are thrilled to announce that Anovo has been recognized as a top workplace by The Commercial Appeal for the…
February 6, 2024
![FDA Releases Final Guidance on Rare Disease Drug Development](https://anovorx.com/wp-content/uploads/2024/04/FDA-Ruling-Post.jpeg)
FDA Releases Final Guidance on Rare Disease Drug Development
The FDA recently released its final guidance on rare disease drug development, which will have several significant implications for orphan…
January 4, 2024
![Egetis Therapeutics & Anovo Unite for MCT8 Patients](https://anovorx.com/wp-content/uploads/2024/04/Partnership-Post-Egetis-Therapeutics.jpeg)
Egetis Therapeutics & Anovo Unite for MCT8 Patients
Egetis Therapeutics is an innovative pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases…
January 2, 2024
![Braynelle’s Story: Living with Dravet Syndrome](https://anovorx.com/wp-content/uploads/2023/12/Braynelle-story.png)
Braynelle’s Story: Living with Dravet Syndrome
Braynelle and Brandon have been managing their son Kai’s diagnosis of Dravet Syndrome since he was four months old. After…
December 3, 2023
![Scott’s Story: Living with Lambert-Eaton Myasthenic Syndrome](https://anovorx.com/wp-content/uploads/2024/04/Patient-Video-Scotts-Story-Living-with-Lambert-Eaton-Myasthenic-Syndrome.jpeg)
Scott’s Story: Living with Lambert-Eaton Myasthenic Syndrome
Experience Scott’s extraordinary journey living with Lambert-Eaton myasthenic syndrome (LEMS), where for over a decade, he’s been his own advocate,…
November 15, 2023
![Kevin’s Story: Living with Lambert-Eaton Myasthenic Syndrome](https://anovorx.com/wp-content/uploads/2023/11/Kevin-story.png)
Kevin’s Story: Living with Lambert-Eaton Myasthenic Syndrome
Meet Kevin, an Anovo patient living with Lambert-Eaton myasthenic syndrome. Despite the challenges he’s faced in not always being able…
November 1, 2023
![Acadia and Anovo Partner to Transform Rett Syndrome Care](https://anovorx.com/wp-content/uploads/2024/04/Partnership-Post-Acadia-Pharmaceuticals.png)
Acadia and Anovo Partner to Transform Rett Syndrome Care
Acadia Pharmaceuticals, Inc. is a pioneering biopharmaceutical company dedicated to transforming the treatment landscape for central nervous system (CNS) disorders….
October 3, 2023
![Anovo Recognized for Creation of “End-to-End” Service Model that Benefits Both Patients and Manufacturers](https://anovorx.com/wp-content/uploads/2023/07/USA-Today-Sponsored-Post.jpeg)
Anovo Recognized for Creation of “End-to-End” Service Model that Benefits Both Patients and Manufacturers
Anovo is excited to announce that we have been featured in an article for USA Today, which details our unique…
September 5, 2023